Stocktoria
Syndax Pharmaceuticals Inc SNDX
Syndax Pharmaceuticals Inc (SNDX) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $172.4M at a -165.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.77 |
| Retained earnings / assets | -2.844 |
| EBIT / assets | -0.516 |
| Equity / liabilities | 0.139 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SNDX | Syndax Pharmaceuticals Inc | 1/9 | -7.54 | — | +627.8% |
| PHAT | Phathom Pharmaceuticals, Inc. | 4/9 | — | — | +216.9% |
| CYRX | Cryoport, Inc. | 4/9 | 0.96 | 10.3 | +12.4% |
| STOK | Stoke Therapeutics, Inc. | 4/9 | 5.29 | — | +404.5% |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | 1/9 | 1.29 | — | -28.3% |
| LQDA | Liquidia Corp | 3/9 | -4.36 | — | +1031.2% |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | 5/9 | -6.24 | — | +45.8% |
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
FAQ
Is SNDX financially healthy?
Syndax Pharmaceuticals Inc's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SNDX pay a dividend?
No, Syndax Pharmaceuticals Inc does not currently pay a dividend.
How profitable is SNDX?
In FY2025, Syndax Pharmaceuticals Inc had a net margin of -165.6% and a return on equity of -441.6%.
What is the analyst price target for SNDX?
The average Wall-Street price target for Syndax Pharmaceuticals Inc is $39.00, about 97.0% above the recent price, from 12 analysts (consensus: strong buy).
Is SNDX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Syndax Pharmaceuticals Inc: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.